SAS Output

19-NOV-2017 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC STUDIES ONLY (TXCA=Y)

88% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1558 1231 79% 1391 -166 1336 -222
ERLYTX 76 189 249% 213 137 205 129
GI 476 196 41% 221 -254 208 -268
GU 450 381 85% 430 -19 428 -22
GYN 57 0 0% 0 -57 0 -57
LEUK 150 56 37% 63 -86 63 -87
LUNG 524 300 57% 339 -184 331 -193
LYMPH 172 6 3% 6 -165 9 -163
MELAN 55 834 1516% 942 887 943 888
MMYEL 147 64 44% 72 -74 79 -68
OTHER 0 32   36 36 37 37
Total 3665 3289   3713 55 3639 -26

19-NOV-2017 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES ONLY (TXCA=N)

88% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 37 33 89% 37 0 33 -4
CCD 0 1373   1551 1551 1557 1557
GU 0 0   0 0 0 0
LEUK 69 4 6% 4 -64 5 -64
LUNG 43 490 1140% 553 510 545 502
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 10   11 11 11 11
PREV 0 90   101 101 100 100
SURV 0 79   89 89 84 84
SXQOL 878 12 1% 13 -864 18 -860
Total 1172 2091   2359 1189 2353 1181

19-NOV-2017 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS

88% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1595 1264 79% 1428 -166 1369 -226
CCD 0 1373   1551 1551 1557 1557
ERLYTX 76 189 249% 213 137 205 129
GI 476 196 41% 221 -254 208 -268
GU 450 381 85% 430 -19 428 -22
GYN 57 0 0% 0 -57 0 -57
LEUK 219 60 27% 67 -151 68 -151
LUNG 567 790 139% 892 325 876 309
LYMPH 225 6 3% 6 -218 9 -216
MELAN 55 834 1516% 942 887 943 888
MMYEL 239 64 27% 72 -166 79 -160
OTHER 0 42   47 47 48 48
PREV 0 90   101 101 100 100
SURV 0 79   89 89 84 84
SXQOL 878 12 1% 13 -864 18 -860
Total 4837 5380   6072 1242 5992 1155

19-NOV-2017 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)

88% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1012 538 53% 607 -404 578 -434
ERLYTX 76 128 168% 144 68 144 68
GI 418 142 34% 160 -257 154 -264
GU 375 270 72% 305 -69 300 -75
GYN 57 0 0% 0 -57 0 -57
LEUK 122 43 35% 48 -73 50 -72
LUNG 441 205 46% 231 -209 225 -216
LYMPH 129 6 5% 6 -122 9 -120
MELAN 55 444 807% 501 446 502 447
MMYEL 85 63 74% 71 -13 78 -7
OTHER 0 32   36 36 37 37
Total 2770 1871   2109 -654 2077 -693

19-NOV-2017 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)

88% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 10 33 330% 37 27 33 23
CCD 0 1163   1314 1314 1347 1347
GU 0 0   0 0 0 0
LEUK 69 4 6% 4 -64 5 -64
LUNG 30 353 1177% 398 368 383 353
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 10   11 11 11 11
PREV 0 77   87 87 84 84
SURV 0 49   55 55 53 53
SXQOL 740 12 2% 13 -726 18 -722
Total 994 1701   1919 927 1934 940

19-NOV-2017 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

88% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1022 571 56% 645 -376 611 -411
CCD 0 1163   1314 1314 1347 1347
ERLYTX 76 128 168% 144 68 144 68
GI 418 142 34% 160 -257 154 -264
GU 375 270 72% 305 -69 300 -75
GYN 57 0 0% 0 -57 0 -57
LEUK 191 47 25% 53 -137 55 -136
LUNG 471 558 118% 630 159 608 137
LYMPH 182 6 3% 6 -175 9 -173
MELAN 55 444 807% 501 446 502 447
MMYEL 177 63 36% 71 -105 78 -99
OTHER 0 42   47 47 48 48
PREV 0 77   87 87 84 84
SURV 0 49   55 55 53 53
SXQOL 740 12 2% 13 -726 18 -722
Total 3764 3572   4031 274 4011 247

19-NOV-2017 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES

88% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 65 1037 1595% 1171 1106 1132 1067
CCD 0 1373   1551 1551 1557 1557
GI 81 27 33% 30 -50 32 -49
GU 215 82 38% 92 -122 90 -125
LEUK 0 4   4 4 5 5
LUNG 53 97 183% 109 56 115 62
LYMPH 7 1 14% 1 -5 2 -5
MELAN 0 747   844 844 852 852
MMYEL 0 64   72 72 79 79
OTHER 0 22   24 24 27 27
PREV 0 90   101 101 100 100
SURV 0 79   89 89 84 84
SXQOL 878 12 1% 13 -864 18 -860
Total 1299 3635   4101 2806 4093 2794

19-NOV-2017 6:10

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

The REPORT Procedure

Detailed and/or summarized report

Table 1

Comm. Phase Study Stat
Center
Open
Date
Months
Open
Total
Regs
Accrual
Goal
Monthly
Accrual
Rate
Date of
Expected Closure or
Temporary Closure
BREAST II S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 SWOG 07JUL2016:00:00:00 16 170 333 15.2 Sep-2018
  II-III NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG 24DEC2014:00:00:00   1   0.2  
  III A011106 Breast, Neoadj, ALTERNATE study ALLIANCE 15FEB2014:00:00:00   51   2.3  
    A011202 Breast, Nodal XRT +/- ALND ALLIANCE     58      
    A011401 Breast, adj, Stage II/III HER2-, weight loss ALLIANCE 29AUG2016:00:00:00   87   8.7  
    A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo ALLIANCE 08DEC2016:00:00:00   21   3.2  
    B51 Breast, Regional Nodal XRT NRG     23      
    B55 Brst, Adj Olaparib for BRCA,TNBC NRG 03JUL2014:00:00:00   21   1.0  
    E2112 Brst,Adv,Exemestane+/-Entinostat ECOG-ACR 02JAN2014:00:00:00   42   1.7  
    NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG 22JAN2015:00:00:00   46   2.3  
    S1207 Brst,Adj,Endocrine+/-Everolimus SWOG 03SEP2013:00:00:00 50 1416 1900 32.7 Jan-2019
    S1222 Brst,Fulv. +/- Ever. +/- Anastr. SWOG 09MAY2014:00:00:00   37 840   Feb-2015 Temp Close
    S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) SWOG 15NOV2016:00:00:00 12 94 1000 12.7 Oct-2023
  OTHER A221405 Breast, ET interruption, Pregnancy Outcomes ALLIANCE 15OCT2015:00:00:00   6   0.8  
    E1Z11 Brst,Genetic Predictors of AIMSS ECOG-ACRIN 10MAY2013:00:00:00   144   0.3  
CCD III A011104 Preoperative Breast MRI ALLIANCE 21FEB2014:00:00:00   10   0.3  
    S1415CD TrACER CSF Standing Order Intervention for FN SWOG 01SEP2016:00:00:00 14 1085 3960 111.8 Dec-2019
  OTHER S1417CD Colorectal, Cost Cohort Study SWOG 13MAY2016:00:00:00 18 133 374 13.8 Apr-2019
ERLYTX II A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib ALLIANCE 06AUG2015:00:00:00   5   0.0  
    S1609 Rare Tumor, Comb Nivo/Ipi SWOG 13JAN2017:00:00:00 10 131 707 14.8 Jan-2021
  II-III A071102 GBM, adj TMZ +/- Veliparib ALLIANCE 19SEP2014:00:00:00   37   0.0  
    ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) COG 16MAY2014:00:00:00   4   0.2  
  OTHER EAY131 MATCH ECOG-ACR 12AUG2015:00:00:00   101   3.7  
GI II A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT ALLIANCE 01DEC2016:00:00:00   10   1.5  
    EA2133 Anal, local recur/met, Cis+5FU vs Taxol/Carbo ECOG-ACRIN 29JAN2016:00:00:00   1   0.0  
    EA2142 GI NEC, Adv G3, EP vs TMZ + CAP ECOG-ACRIN 06NOV2015:00:00:00   4   0.5  
    NRGGI002 Rectal, Ph II, Sensitization using TNT NRG 12OCT2016:00:00:00   3   0.2  
    S1505 Panc,Resect, Perioperative Chemo SWOG 12OCT2015:00:00:00 25 103 112 4.0 Jan-2018
    S1513 Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888 SWOG 01SEP2016:00:00:00 14 108 143 11.5 Feb-2018
    S1613 mCRC, Adv/Met, TP vs CETIRI SWOG 09OCT2017:00:00:00 1 0 130    
  II-III N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX ALLIANCE 13JAN2012:00:00:00   132   2.5  
  III R0848 Panc, Adj, Erlotinib v ChemoRT NRG 01MAR2014:00:00:00   20   0.0  
GU II EA8141 UTUC, HG, Chemo then Surg ECOG-ACR 27JAN2015:00:00:00   8   0.0  
    S1314 Blad, COXEN Neoadj. Chemo + Cyst SWOG 11JUL2014:00:00:00 40 233 230 7.2 Nov-2017
    S1500 pRCC,Adv, Sunitinib vs MET inhib SWOG 05APR2016:00:00:00 19 56 180 2.8 Jun-2021
    S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab SWOG 07FEB2017:00:00:00 9 21 148 3.2 Mar-2021
  II-III NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG 30DEC2016:00:00:00   1   0.2  
  III A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) ALLIANCE 01JUL2015:00:00:00   2   0.0  
    EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) ECOG-ACR 02FEB2017:00:00:00   3   0.5  
    R0924 Pros, NADT+WPRT vs. NADT+P&SV RT NRG 07JUL2011:00:00:00   58   2.2  
    S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG SWOG 07FEB2017:00:00:00 9 51 969 7.2 Jul-2028
LEUK I S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP SWOG 01APR2014:00:00:00 43 37 38 0.3 Jan-2018
  I-II S1318 ALL, Age 65+, Ph±, Blinatumomab SWOG 12JAN2015:00:00:00   47 44   Sep-2017 Temp Close
  III E1910 BCR-ABL-neg, B ALL, Blinatumomab ECOG-ACRIN 23DEC2013:00:00:00   67   1.5  
    E2906 AML, Age 60+, Clo vs Dauno+Cy ECOG-ACRIN 24FEB2011:00:00:00   75   0.0  
  OTHER NHLBIMDS LEUK, National MDS Study ECOG-ACRIN 05APR2016:00:00:00   5   0.3  
LUNG II R1306 NSCLC,Adv,ALK/EGFR,TargetAgents NRG 04NOV2013:00:00:00   8   0.0  
    S1400F Non-Match: MEDI4736 + Tremelimumab SWOG 02OCT2017:00:00:00 1 0 132    
    S1400G HRRD: Talazoparib (BMN 673) SWOG 07FEB2017:00:00:00 9 32 60 3.3 Jul-2018
    S1507 NSCLC, Adv, Kras Mut, Trametinib + Docetaxel SWOG 18JUL2016:00:00:00 16 44 53 3.0 Jan-2018
  II-III NRGCC003 SCLC, PCI or HA-PCI NRG 07DEC2015:00:00:00   4   0.5  
    S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab SWOG 25MAR2015:00:00:00 31 150 605 6.7 Jul-2023
  III A081105 ALCHEMIST1, EGFR mut, Erlotinib ALLIANCE 02JAN2014:00:00:00   29   1.3  
    C30610 SCLC, Thoracic RT ALLIANCE 21MAR2008:00:00:00   54   0.7  
    E4512 ALCHEMIST2, ALK mut, Crizotinib ECOG-ACR 18AUG2014:00:00:00   6   0.5  
    EA5142 ALCHEMIST3, Non-match, Nivolumab ECOG-ACRIN 16MAY2016:00:00:00   26   2.3  
    S1400I Non-Match: Nivo + Ipi vs Nivo SWOG 18DEC2015:00:00:00 23 245 350 7.8 Dec-2018
  OTHER A151216 ALCHEMIST0 - screening ALLIANCE 06FEB2014:00:00:00   401   19.3  
    S1400 SCCA,Adv, Biomarker Master SWOG 15JUN2014:00:00:00 41 1425   25.5  
  PILOT S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC SWOG 03NOV2017:00:00:00 0 0 28    
LYMPH II S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob SWOG 10AUG2017:00:00:00 3 0 150 0.0 > 15 Yrs
  III A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo ALLIANCE 15JUL2016:00:00:00   4   0.5  
MELAN II E3612 MELAN,Adv Ipilimumab±Bevacizumab ECOG-ACR     6      
    S1320 Adv, BRAF mut, Inter v Contin SWOG 22JUL2014:00:00:00 39 185 280 6.3 Jan-2019
    S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) SWOG 20OCT2016:00:00:00 12 3 77 0.3 > 15 Yrs
    S1607 MELAN, Adv, T-VEC, MK-3475 SWOG 02OCT2017:00:00:00 1 0 64    
    S1616 MELAN, Adv, Ipilimumab ± Nivolumab SWOG 17JUL2017:00:00:00 4 2 94 0.5 > 15 Yrs
  II-III EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim ECOG-ACRIN 01MAR2016:00:00:00   36   1.2  
  III EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T ECOG-ACR 15DEC2015:00:00:00   23   1.2  
    S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 SWOG 15OCT2015:00:00:00 25 1345 1378 54.5 Nov-2017
MMYEL I-II S1211 MM,High Risk, RVD+/-ELO SWOG 27OCT2012:00:00:00   142 110   Jun-2016 Temp Close
  III E1A11 MM, frontline, BLD vs CLD ECOG-ACRIN 22NOV2013:00:00:00   149   5.5  
OTHER I-II A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II ALLIANCE 26JAN2015:00:00:00   6   0.7  
  II A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo ALLIANCE 02SEP2014:00:00:00   2   0.2  
    A091305 HN, Adv, Thyroid PPAR agonist + Chemo ALLIANCE 01SEP2014:00:00:00   2   0.0  
    A091401 Sarc, ALLIANCE 18JUN2015:00:00:00   5   0.0  
    A091404 HN, AR+, Enzalutamide ALLIANCE 25SEP2015:00:00:00   7   0.8  
    EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp ECOG-ACRIN 29MAR2016:00:00:00   4   0.5  
    NRGBN001 HN, novel vs. std chemoradiation + chemo NRG 28AUG2015:00:00:00   1   0.0  
  II-III G0281 Ovar, Recur/prog LG, IC chemo vs trametinib NRG 27FEB2014:00:00:00   1   0.0  
    G0286B Adv Endometrial,Metformin/Chemo NRG     1      
    NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG 06FEB2016:00:00:00   3   0.0  
    NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG 21APR2014:00:00:00   4   0.2  
    R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux NRG 18MAR2013:00:00:00   3   0.0  
  III G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT NRG 12APR2010:00:00:00   1   0.2  
    N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC ALLIANCE     4      
    NRGGY004 Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo NRG 04FEB2016:00:00:00   6   0.3  
    R0724 Cervical, Chem+RT +/- Adj. Chemo NRG 15JAN2014:00:00:00   1   0.0  
    R0920 HN, Adv, Postop IMRT ± Cetuximab NRG 24DEC2013:00:00:00   11   0.2  
  OTHER EAQ152 Communication & education in tumor profiling ECOG-ACR 26SEP2016:00:00:00   11   0.3  
PREV II EA1141 Breast, Abbrev. MRI vs Digital Tomosynthesis ECOG-ACR 02SEP2016:00:00:00   44   7.3  
  III A211102 Breast, Atypia via RPFNA, Metformin v Placebo ALLIANCE 01FEB2015:00:00:00   3   0.0  
    S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac SWOG 01MAR2013:00:00:00 56 164 480 2.8 Feb-2027
  OTHER A211201 Breast Density, MA.32 companion ALLIANCE 22AUG2012:00:00:00   14   0.0  
SURV III E1Q11 EROS: Reproductive Health in Cancer Survivors ECOG-ACR 30SEP2015:00:00:00   7   0.7  
    S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol SWOG 15SEP2017:00:00:00 2 2 817    
  OTHER EA9131 Leuk, Strategy to decrease early APL deaths ECOG-ACR 16AUG2017:00:00:00   2   0.6  
    S1316 Compar. Effectiv. Trial for MBO SWOG 09MAR2015:00:00:00 32 124 200 7.7 Aug-2018
SXQOL III A221101 Glioma, Nuvigil/Placebo Fatigue ALLIANCE 03JUN2013:00:00:00   17   0.3  
    A221102 Brst,AI Arthralgia,Testosterone ALLIANCE 07SEP2012:00:00:00   10   0.0  
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

19-NOV-2017 6:10

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

The REPORT Procedure

Detailed and/or summarized report

Table 1

Phase Comm. Int
grp
Stat
Center
Study NCIPROTO CA
Cntrl
Study
Temp
Close
OTHER BREAST Y ECOG-ACRIN E1Z11 Brst,Genetic Predictors of AIMSS E1Z11 Y  
    Y ALLIANCE A221405 Breast, ET interruption, Pregnancy Outcomes A221405 Y  
  CCD N   S1417CD Colorectal, Cost Cohort Study   Y  
  ERLYTX Y ECOG-ACR EAY131 MATCH EAY131 N  
  LEUK Y ECOG-ACRIN NHLBIMDS LEUK, National MDS Study NHLBI-MDS Y  
  LUNG Y SWOG S1400 SCCA,Adv, Biomarker Master S1400 N  
    Y ALLIANCE A151216 ALCHEMIST0 - screening A151216 N  
  OTHER Y ECOG-ACR EAQ152 Communication & education in tumor profiling EAQ152 Y  
  PREV Y ALLIANCE A211201 Breast Density, MA.32 companion A211201 Y  
  SURV Y SWOG S1316 Compar. Effectiv. Trial for MBO S1316 Y  
    Y ECOG-ACR EA9131 Leuk, Strategy to decrease early APL deaths EA9131 Y  
I LEUK N   S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP   N  
I-II LEUK Y SWOG S1318 ALL, Age 65+, Ph±, Blinatumomab S1318 N Y
  MMYEL Y SWOG S1211 MM,High Risk, RVD+/-ELO S1211 N Y
  OTHER Y ALLIANCE A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II A091304 N  
II BREAST Y SWOG S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 S1416 N  
  ERLYTX Y SWOG S1609 Rare Tumor, Comb Nivo/Ipi S1609 N  
    Y ALLIANCE A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib A071401 N  
  GI Y SWOG S1613 mCRC, Adv/Met, TP vs CETIRI S1613 N  
    Y SWOG S1513 Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888 S1513 N  
    Y SWOG S1505 Panc,Resect, Perioperative Chemo S1505 N  
    Y ECOG-ACRIN EA2142 GI NEC, Adv G3, EP vs TMZ + CAP EA2142 N  
    Y NRG NRGGI002 Rectal, Ph II, Sensitization using TNT NRG-GI002 N  
    Y ALLIANCE A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT A021501 N  
    Y ECOG-ACRIN EA2133 Anal, local recur/met, Cis+5FU vs Taxol/Carbo EA2133 Y  
  GU Y SWOG S1314 Blad, COXEN Neoadj. Chemo + Cyst S1314 N  
    Y SWOG S1500 pRCC,Adv, Sunitinib vs MET inhib S1500 N  
    Y SWOG S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab S1605 N  
    Y ECOG-ACR EA8141 UTUC, HG, Chemo then Surg EA8141 N  
  LUNG Y SWOG S1400G HRRD: Talazoparib (BMN 673) S1400G N  
    Y SWOG S1400F Non-Match: MEDI4736 + Tremelimumab S1400F N  
    Y SWOG S1507 NSCLC, Adv, Kras Mut, Trametinib + Docetaxel S1507 N  
    Y NRG R1306 NSCLC,Adv,ALK/EGFR,TargetAgents RTOG-1306 N  
  LYMPH Y SWOG S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob S1608 N  
  MELAN Y SWOG S1320 Adv, BRAF mut, Inter v Contin S1320 N  
    Y SWOG S1607 MELAN, Adv, T-VEC, MK-3475 S1607 N  
    Y SWOG S1616 MELAN, Adv, Ipilimumab ± Nivolumab S1616 N  
    Y SWOG S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) S1512 N  
    Y ECOG-ACR E3612 MELAN,Adv Ipilimumab±Bevacizumab E3612 N  
  OTHER Y NRG NRGBN001 HN, novel vs. std chemoradiation + chemo NRG-BN001 N  
    Y ALLIANCE A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo A091202 N  
    Y ALLIANCE A091401 Sarc, A091401 N  
    Y ALLIANCE A091305 HN, Adv, Thyroid PPAR agonist + Chemo A091305 N  
    Y ALLIANCE A091404 HN, AR+, Enzalutamide A091404 N  
    Y ECOG-ACRIN EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp EA3132 N  
  PREV Y ECOG-ACR EA1141 Breast, Abbrev. MRI vs Digital Tomosynthesis EA1141 Y  
PILOT LUNG Y SWOG S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC S1619 N  
II-III BREAST Y NRG NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG-BR002 N  
  ERLYTX Y ALLIANCE A071102 GBM, adj TMZ +/- Veliparib A071102 N  
    Y COG ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) ARST1321 N  
  GI Y ALLIANCE N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX N1048 Y  
  GU Y NRG NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG-GU002 N  
  LUNG Y SWOG S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab S1403 N  
    Y NRG NRGCC003 SCLC, PCI or HA-PCI NRG-CC003 Y  
  MELAN Y ECOG-ACRIN EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim EA6141 N  
  OTHER Y NRG NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG-GY005 Y  
    Y NRG G0286B Adv Endometrial,Metformin/Chemo GOG-0286B Y  
    Y NRG R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux RTOG-1216 Y  
    Y NRG NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG-HN001 Y  
    Y NRG G0281 Ovar, Recur/prog LG, IC chemo vs trametinib GOG-0281 Y  
III BREAST N   S1222 Brst,Fulv. +/- Ever. +/- Anastr.   N Y
    Y SWOG S1207 Brst,Adj,Endocrine+/-Everolimus S1207 Y  
    Y SWOG S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) S1418 Y  
    Y ALLIANCE A011202 Breast, Nodal XRT +/- ALND A011202    
    Y ALLIANCE A011106 Breast, Neoadj, ALTERNATE study A011106 N  
    Y NRG B51 Breast, Regional Nodal XRT NSABP-B-51 Y  
    Y ALLIANCE A011401 Breast, adj, Stage II/III HER2-, weight loss A011401 Y  
    Y NRG NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG-BR003 N  
    Y ECOG-ACR E2112 Brst,Adv,Exemestane+/-Entinostat E2112 Y  
    Y ALLIANCE A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo A011502 Y  
    Y NRG B55 Brst, Adj Olaparib for BRCA,TNBC NSABP-B-55 Y  
  CCD Y SWOG S1415CD TrACER CSF Standing Order Intervention for FN S1415CD Y  
    Y ALLIANCE A011104 Preoperative Breast MRI A011104 Y  
  GI Y NRG R0848 Panc, Adj, Erlotinib v ChemoRT RTOG-0848 Y  
  GU Y SWOG S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG S1602 Y  
    Y NRG R0924 Pros, NADT+WPRT vs. NADT+P&SV RT RTOG-0924 Y  
    Y ECOG-ACR EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) EA8143 Y  
    Y ALLIANCE A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) A031102 Y  
  LEUK Y ECOG-ACRIN E2906 AML, Age 60+, Clo vs Dauno+Cy E2906 Y  
    Y ECOG-ACRIN E1910 BCR-ABL-neg, B ALL, Blinatumomab E1910 N  
  LUNG Y SWOG S1400I Non-Match: Nivo + Ipi vs Nivo S1400I Y  
    Y ALLIANCE C30610 SCLC, Thoracic RT CALGB-30610 Y  
    Y ALLIANCE A081105 ALCHEMIST1, EGFR mut, Erlotinib A081105 N  
    Y ECOG-ACRIN EA5142 ALCHEMIST3, Non-match, Nivolumab EA5142 N  
    Y ECOG-ACR E4512 ALCHEMIST2, ALK mut, Crizotinib E4512 N  
  LYMPH Y ALLIANCE A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo A051301 N  
  MELAN Y SWOG S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 S1404 Y  
    Y ECOG-ACR EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T EA6134 Y  
  MMYEL Y ECOG-ACRIN E1A11 MM, frontline, BLD vs CLD E1A11 Y  
  OTHER Y NRG R0920 HN, Adv, Postop IMRT ± Cetuximab RTOG-0920 Y  
    Y ALLIANCE N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC N0577 N  
    Y NRG G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT GOG-0263 Y  
    Y NRG R0724 Cervical, Chem+RT +/- Adj. Chemo RTOG-0724 Y  
    Y NRG NRGGY004 Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo NRG-GY004 Y  
  PREV Y SWOG S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac S0820 Y  
    Y ALLIANCE A211102 Breast, Atypia via RPFNA, Metformin v Placebo A211102 Y  
  SURV Y SWOG S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol S1501 Y  
    Y ECOG-ACR E1Q11 EROS: Reproductive Health in Cancer Survivors E1Q11 Y  
  SXQOL Y ALLIANCE A221101 Glioma, Nuvigil/Placebo Fatigue A221101 Y  
    Y ALLIANCE A221102 Brst,AI Arthralgia,Testosterone A221102 Y  

19-NOV-2017 6:10

PHASE III SWOG COORDINATED OPEN STUDIES

SORTED BY STUDY ID

The REPORT Procedure

Detailed and/or summarized report

Table 1

Protocol
Number
Study Accrual
Goal
Open
Stat/Date
Months
Open
Accrual
as of
01Jan02
Current Accrual Proj.
Annual
Accr.
Rate
EXPCLOSE Proj.
Study
Duration
(Years)
S0820 S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac (PREV) 480 Y-03/01/13 56 164 164 34 Feb-2027 14.0
S1007 S1007 Breast,Adj,N1,Endocrine+/-Chemo (BREAST) 4000 Y-01/15/11 82 5083 5083 398 Mar-2015 4.2
S1207 S1207 Brst,Adj,Endocrine+/-Everolimus (BREAST) 1900 Y-09/03/13 50 1416 1416 392 Jan-2019 5.4
S1222 Brst,Fulv. +/- Ever. +/- Anastr. (BREAST) 840 T-05/09/14 42 37 37 0 > 15 Yrs > 15 Yrs
S1400I S1400I Non-Match: Nivo + Ipi vs Nivo (LUNG) 350 Y-12/18/15 23 245 245 94 Dec-2018 3.0
S1403 S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab (LUNG) 605 Y-03/25/15 31 150 150 80 Jul-2023 8.3
S1404 S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 (MELAN) 1378 Y-10/15/15 25 1345 1345 654 Nov-2017 2.1
S1415CD S1415CD TrACER CSF Standing Order Intervention for FN (CCD) 3960 Y-09/01/16 14 1085 1085 1342 Dec-2019 3.3
S1418 S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) (BREAST) 1000 Y-11/15/16 12 94 94 152 Oct-2023 6.9
S1501 S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol (SURV) 817 Y-09/15/17 2 2 2      
S1602 S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG (GU) 969 Y-02/07/17 9 51 51 86 Jul-2028 11.4
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.